Brokerages Set Viridian Therapeutics, Inc. (NASDAQ:VRDN) Target Price at $35.70

Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) have earned an average rating of “Moderate Buy” from the twelve brokerages that are presently covering the stock, MarketBeat.com reports. Three analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $35.70.

VRDN has been the topic of a number of recent analyst reports. TD Cowen started coverage on shares of Viridian Therapeutics in a report on Monday, November 25th. They set a “buy” rating on the stock. HC Wainwright reiterated a “buy” rating and set a $34.00 target price on shares of Viridian Therapeutics in a research report on Monday, December 16th. Needham & Company LLC restated a “buy” rating and set a $38.00 price target on shares of Viridian Therapeutics in a report on Tuesday, January 7th. Royal Bank of Canada boosted their price target on shares of Viridian Therapeutics from $44.00 to $47.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 17th. Finally, Wells Fargo & Company reiterated an “equal weight” rating and set a $27.00 price objective (down previously from $37.00) on shares of Viridian Therapeutics in a research report on Thursday, December 19th.

Institutional Investors Weigh In On Viridian Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. R Squared Ltd bought a new position in Viridian Therapeutics in the 4th quarter valued at $26,000. Foresite Capital Management VI LLC purchased a new stake in shares of Viridian Therapeutics during the fourth quarter valued at $38,000. AlphaQuest LLC grew its holdings in shares of Viridian Therapeutics by 119.0% in the fourth quarter. AlphaQuest LLC now owns 2,795 shares of the company’s stock worth $54,000 after purchasing an additional 1,519 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new position in Viridian Therapeutics in the 3rd quarter worth about $149,000. Finally, Summit Investment Advisors Inc. lifted its holdings in Viridian Therapeutics by 24.7% during the 4th quarter. Summit Investment Advisors Inc. now owns 7,646 shares of the company’s stock valued at $147,000 after buying an additional 1,516 shares in the last quarter.

Viridian Therapeutics Stock Down 2.4 %

NASDAQ:VRDN opened at $15.54 on Friday. Viridian Therapeutics has a fifty-two week low of $11.40 and a fifty-two week high of $27.20. The firm has a market cap of $1.23 billion, a P/E ratio of -3.61 and a beta of 1.32. The firm has a 50-day simple moving average of $18.41 and a two-hundred day simple moving average of $19.69. The company has a debt-to-equity ratio of 0.04, a quick ratio of 18.55 and a current ratio of 18.55.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.